Eculizumab hepatotoxicity in pediatric aHUS

Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Hayes, Wesley (VerfasserIn) , Tschumi, Sibylle (VerfasserIn) , Ling, Simon C. (VerfasserIn) , Feber, Janusz (VerfasserIn) , Kirschfink, Michael (VerfasserIn) , Licht, Christoph (VerfasserIn)
Dokumenttyp:	Article (Journal)
Sprache:	Englisch
Veröffentlicht:	2015
In:	Pediatric nephrology Year: 2014, Jahrgang: 30, Heft: 5, Pages: 775-781
ISSN:	1432-198X
DOI:	10.1007/s00467-014-2990-5
Online-Zugang:	Verlag, Volltext: https://doi.org/10.1007/s00467-014-2990-5
Verfasserangaben:	Wesley Hayes, Sibylle Tschumi, Simon C. Ling, Janusz Feber, Michael Kirschfink, Christoph Licht

Beschreibung
Zusammenfassung:	Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.
Beschreibung:	Published online: 22 November 2014 Gesehen am 16.07.2020
Beschreibung:	Online Resource
ISSN:	1432-198X
DOI:	10.1007/s00467-014-2990-5